The aim of this study was determine whether the cytosine-to-thymine mutation at base 677 of the gene for methylenetetrahydrofolate reductase (C677T MTHFR), which has been associated with neural tube defects, is also associated with congenital cardiac malformations. STUDY DESIGN: Amniotic fluid homocysteine levels were measured and the presence or absence of the C677T MTHFR mutation in amniocytes was determined in stored amniotic fluid obtained from 26 pregnancies complicated by isolated (presumed multifactorial) fetal cardiac defects and from 116 normal pregnancies.
By definition, isolated structural malformations are not associated with other anomalies and do not occur as part of a genetic syndrome. Most isolated malformations are considered to be multifactorial in origin, meaning that there is a presumed genetic basis for the defect that is susceptible to or modified by environmental factors. The responsible genes and pathogenic influences for a few structural malformations are only now coming to light. The genes that cause cardiac and neural tube defects are of greatest interest, because these malformations are the two most common multifactorial anomalies worldwide. 1 It is now generally acknowledged that folate nutriture is one of the environmental influences on neural tube defect formation. Although Hibbard and Smithells 2, 3 postulated more than 30 years ago that folate deficiency caused neural tube defects, this causative link did not gain wide recognition until the Medical Research Council Vitamin Study in 1991. 4 That prospective, randomized, double-blind study, which included 1817 women who had borne at least one child with a neural tube defect, definitively showed that periconceptional folic acid supplementation reduced the recurrence risk of neural tube defects by 72%. A subsequent study by Czeizel and Dudas 5 showed that periconceptional folic acid supplementation reduced the incidence of first occurrences as well.
The connection between neural tube defects and folate can be explained by a mutation in the gene for the enzyme methylenetetrahydrofolate reductase (MTHFR). As can be seen in Fig 1, MTHFR is critical for the folatedependent remethylation of homocysteine to methionine. Deficiency of both this enzyme and folate leads to elevated serum and amniotic fluid levels of homocysteine; folic acid supplementation apparently overcomes the block and normalizes homocysteine levels. 6 In 1995 van der Put et al 7 demonstrated that children with neural tube defects and their parents were significantly more likely to be homozygous for the C677T mutation in the gene for MTHFR, and Steegers-Theunissen et al 8 showed that amniotic fluid homocysteine levels were abnormally high in pregnancies complicated by fetal neural tube defects. It is not currently known whether the mutation, the high homocysteine levels, or some other mechanism actually causes neural tube defects. It is interesting that either elevated serum homocysteine levels or the C677T MTHFR mutation, or both, have also been associated with premature cardiovascular disease and hereditary thrombophilia in adults. [9] [10] [11] [12] [13] [14] Several pieces of data now suggest that multifactorial cardiac defects may also be associated with this mutation. A reanalysis of the data from Czeizel's prospective randomized study 15 has shown not only that there were no neural tube defects among the offspring of supplemented mothers but also that there were significantly fewer obstructive urinary tract defects and cardiac anomalies (primarily ventricular septal defects). In retrospective case-control studies both Botto et al 16 and Shaw et al 17 reported an association between periconceptional multivitamin use and reduced risk for fetal conotruncal cardiac defects, and a subanalysis of the Baltimore-Washington Infant study data found an inverse relationship between daily maternal folic acid intake and the offspring's incidence of cardiac outflow tract defects. 18 To our knowledge, however, no one has established that the C677T MTHFR mutation is linked to multifactorial cardiac defects, nor have amniotic fluid homocysteine levels in such cases been evaluated. We therefore hypothesized that the C677T MTHFR mutation and high amniotic fluid levels of homocysteine are causally linked to isolated congenital cardiac malformations. To investigate this hypothesis, we studied stored amniotic fluid specimens obtained from patients with pregnancies complicated by isolated fetal cardiac defects and from patients with normal pregnancies.
Methods
Amniotic fluid samples. With institutional review board approval, we used our computerized genetics database to identify all cases seen at the University of Alabama Prenatal Genetics Clinic from January 1988 to January 1998 in which an isolated (nonsyndromic) fetal cardiac defect was diagnosed by ultrasonography and an amniocentesis had been performed. This tertiary referral clinic is the major provider of prenatal genetic services for our state's gravid residents. Approximately 90% of referred patients are white, and most are middle-class and insured. The University of Alabama patients seen in this clinic are primarily African American and insured through Medicaid.
Clinic, hospital, and autopsy records (where applicable) were reviewed for each case to confirm that the cardiac defect was isolated. We then surveyed our bank of stored specimens to determine the availability of corresponding amniotic fluid samples. We excluded any case in which the fetus had additional anomalies, aneuploidy, a known genetic syndrome, or exposure to a teratogen or diabetes and we also excluded all cases for which adequate stored amniotic fluid was not available.
Because of the considerable time and expense involved in retrieving, characterizing, and analyzing control samples, we explored the possibility of using a group of samples that had served as control samples for previous studies of the relationship between the C677T MTHFR mutation and neural tube defects 19, 20 and for a study (as yet unpublished) evaluating the C677T MTHFR mutation and isolated hydrocephalus. These amniotic fluid samples had been selected from a list of all samples obtained from women who had undergone genetic amniocentesis at the same clinic as the study patients but who had a pregnancy confirmed to be normal by karyotype, ultrasonographic examination, and neonatal examination. After computerized descriptive data were used to create a list of potential acceptable control samples, each sample was randomly assigned a computer-generated priority number (with the SAS RANUNI function; SAS Institute, Inc, Cary, NC) and sorted accordingly. Samples were then retrieved from storage according to priority number, and the first adequate fluid samples located were selected as control specimens; 116 control samples had been required for these previous studies.
We compared the current study group with this potential control group with respect to the two factors that could theoretically influence the results and found the two groups were similar in terms of maternal race (27% black, 69% white, and 4% other in the study group; 20% black, 78% white, and 2% other in the control group; difference not statistically significant) and the amount of time the amniotic fluid had been in storage (in the study group: mean, 4.9 years; range, 0-11 years; in the control group: mean, 4.9 years; range, 1-10 years; difference not statistically significant). Because the women who contributed these control samples were seen in the same clinic as the study patients, they were also of similar socioeconomic background (which could influence folate nutriture). We did not consider gestational age at the time of the amniocentesis, because amniotic fluid homocysteine levels are not correlated with gestational age. 8 After we had assured ourselves that the control samples were appropriate for this study, we retrieved the results of the previous analyses for statistical comparison. The analytic methods described here were identical to those used to evaluate the control samples; thus the analyses of study and control samples are described together.
Homocysteine assay. Stored excess amniotic fluid obtained at the time of genetic amniocentesis was retrieved for each case and control patient. All amniocenteses were performed aseptically under ultrasonographic guidance by an experienced operator with a 22-gauge spinal needle, and all fluid samples were prepared for assay or storage within 6 hours of the procedure. A portion of each sample was removed for genetic studies, and any excess fluid was transferred into a plastic tube and stored at -20°C without interruption until it was thawed for assay. The stability of homocysteine under similar storage conditions has been confirmed. 21 Total homocysteine levels were measured with a high-performance liquid chromatography-fluorescence method as previously described elsewhere. 22 The coefficient of variation of homocysteine determination with pooled plasma samples in our laboratory is approximately 6%.
MTHFR genotype analysis. After a fluid sample was removed for homocysteine analysis, the remaining amniotic fluid was centrifuged at 8000g for 10 minutes. All but 50 µL of the supernatant was decanted, and the cell pellet was resuspended. The MTHFR genotypes were analyzed after extraction of genomic deoxyribonucleic acid (DNA) from the suspension with a DNA isolation kit (Puregene DNA Isolation Kit; Gentra Systems, Inc, Minneapolis, Minn). Thirty-five polymerase chain reaction cycles were followed by overnight HinfI (New England Biolabs, Inc, Beverly, Mass) treatment at 37°C, as originally described by Frosst et al. 21 The fragments were then separated by electrophoresis with a 2.5% agarose gel (Life Technologies, Inc, Rockville, Md) in 2.0-mmol/L tris(hydroxymethyl)aminomethane borate buffer, pH 8.5, containing 2-mmol/L ethylenediaminetetraacetic acid. If the C677T MTHFR mutation is present (leading to a substitution of valine for alanine in the protein product), the 198-base pair (bp) fragment is cleaved to 175-bp and 23-bp fragments by the enzyme treatment.
Statistical analysis. The mean homocysteine levels and the incidences of abnormal genotype (heterozygosity or homozygosity for the C677T MTHFR mutation) were determined for both case and control subjects. The proportion of samples in each group with amniotic fluid homocysteine levels >90th percentile (>1.85 µmol/L according to previous work 19 ) was determined. The amniotic fluid homocysteine levels in case patients and control subjects were compared by t test after logarithmic transformation, and the genotypic frequencies were compared by 2-tailed Fisher exact test. P < .05 was considered significant. Odds ratios were computed with the Mantel-Haenszel method and were considered significant if the 95% confidence intervals did not include 1.0.
Results
We identified 26 patients who had pregnancies complicated by isolated fetal cardiac defects and who had com-plete records and adequate stored amniotic fluid available. This number cannot be used to derive an incidence, because a large proportion of women whose fetuses had an apparently isolated cardiac defect declined invasive testing, and many fetuses with cardiac anomalies identified in our clinic were ultimately given specific diagnoses (eg, Noonan syndrome, Holt-Oram syndrome). The defect types and their MTHFR gene status are listed in Table  I . Nine patients whose fetuses had a cardiac defect were heterozygous or homozygous for the C677T MTHFR mutation.
The results of the analyses performed in these 26 cases are listed in Table II . As these data illustrate, the amniotic fluid samples obtained from the cases had higher mean homocysteine levels (1.7 ± 1.7 vs 1.0 ± 0.7 µmol/L; P = .07), included significantly more samples with homocysteine levels >90th percentile (27% vs 9%; P = .02), and had significantly more C677T MTHFR mutations (35% vs 13%; P = .01). Fifty percent of the amniotic fluid samples obtained from the cases had evidence of abnormal homocysteine metabolism (either MTHFR mutation or abnormal homocysteine level, 50% vs 20%; P = .003), and in 12% both the amniotic fluid homocysteine level and the MTHFR gene were abnormal (P = .006).
Comment
Our data indicate that the same pathogenetic mechanism that causes neural tube defects, involving the C677T MTHFR mutation and elevated amniotic fluid homocysteine levels, is at least partially responsible for certain cardiac defects as well. Although disruption of the metabolic pathway pictured in Fig 1 appears to account for a substantial portion of defects, other mechanisms must also be operational, because folic acid supplementation does not prevent 28% of neural tube defect recurrences, 4 and only 50% of women whose fetuses had cardiac defects in our study had any evidence of abnormal homocysteine metabolism. Our data can be added to the growing body of largely epidemiologic and case-control data implicating folate deficiency in defects as diverse as cleft lip and palate, urinary tract abnormalities, limb deformities, Down syndrome, vascular disease, thrombosis, and even schizophrenia. 9, 10, 12, [23] [24] [25] [26] [27] [28] Although it seems hard to believe that a single biochemical abnormality could have such far-reaching effects, consideration of the homocysteine metabolic pathway clarifies why this is likely to be so.
It is possible that the elevated homocysteine level resulting from the C677T MTHFR mutation is responsible for the observed pathologic changes. Data from studies of individuals with the C677T MTHFR mutation and atherosclerotic heart disease indicate that the cardiovascular damage is caused by the resultant high homocysteine level and not by the mutation itself. The C677T MTHFR mutation has been found to have a more than 3-fold higher incidence among individuals with coronary artery disease and severe coronary artery stenosis 9, 10 and is significantly more common among patients with myocardial infarction, cerebrovascular disease, and peripheral vascular disease. 12 However, Rozen et al 23 have shown that this mutation is associated with cardiovascular disease only among patients who have folate levels <50% of normal. This indicates that the mutation alone is necessary but not sufficient to cause vascular damage; it must be accompanied by inadequate folic acid nutriture leading to elevated homocysteine levels. Other biologic and epidemiologic data confirm this conclusion. 24 In terms of congenital malformations, it is certainly possible that the high amniotic fluid homocysteine level itself is teratogenic.
It is also possible that the C677T MTHFR mutation leads to a disruption of metabolic pathways far removed from the homocysteine cycle, the proposed mechanism by which the C677T MTHFR mutation causes neuropsychiatric disease. It has been demonstrated that S-adenosylmethionine eventually affects the turnover of monoamines, including serotonin and dopamine. 25 The incidence of the C677T MTHFR mutation, which presumably leads to decreased S-adenosylmethionine levels and thus decreased monoamines, is significantly increased among individuals with schizophrenia (odds ratio, 1.9; 95% confidence interval, 1.3-2.9) and major depression (odds ratio, 2.8; 95% confidence interval, 1.3-6.4). 25 It is therefore possible that the C677T MTHFR mutation also has far-reaching (as yet unknown) teratogenic effects, although there are currently no data to support this theory.
In light of all that is known about the homocysteine pathway and the C677T MTHFR mutation, it seems most likely that the influence on development is mediated through its effect on methionine. The result of the homocysteine pathway is the production of methionine and S-adenosylmethionine. Only one methyl group distinguishes homocysteine from methionine, and methionine is the immediate precursor of S-adenosylmethionine, the major intracellular methyl donor for DNA, protein, and lipid reactions. 26 Methyl groups are essential for several vital biochemical processes. Methyl groups are required for the replication of both DNA and ribonucleic acid, and DNA hypomethylation is associated with chromosomal instability and abnormal segregation. In cultured plant and animal cells and in human tumors, DNA hypomethylation has been shown to cause chromosomal instability and aneuploidy. 29, 30 Consistent with this, the C677T MTHFR mutation has been associated with Down syndrome. James et al 26 evaluated 50 mothers of Down syndrome children and 50 age-matched control subjects and found that the mothers of children with Down syndrome had significantly higher serum homocysteine concentrations. Further, the risk of having a child with Down syndrome was increased 2.6 times (95% confidence interval, 1.2-5.8 times) among those mothers with the C677T MTHFR mutation. DNA methylation results in inhibition of gene expression and is fundamental to the epigenetic control of gene transcription. Thus DNA methylation controls cellular proliferation and differentiation. Methylation also contributes to the regulation of the production of extracellular matrix components and plasma membrane constituents necessary for cell-to-cell recognition, cellular migration, and induction processes. Finally, methyl groups are by definition essential to the transmethylation reactions vital to the synthesis of amino acids and proteins, the pyrimidine thymine, S-adenosylmethionine, and a host of other biomolecules, including choline, acetylcholine, creatine, carnitine, and such lipids as myelin. Thus the effects of methylation are legion and complex. Each of these methylation-dependent processes and substances is critical for normal tissue growth and maturation. If any of the molecules or cellular products related to methylation and requisite for cellular proliferation, differentiation, adhesion, migration, or programmed death (apoptosis) are deficient or dysfunctional, slowed or interrupted tissue growth and development could result. The link between slowed growth and birth defects makes sense, because a variety of congenital defects are caused by slowed growth leading to incorrect timing of normal developmental events. This etiologic mechanism seems most likely to explain the link between the C677T MTHFR mutation and a variety of birth defects, because all the congenital anomalies reported to be associated with folate deficiency could potentially arise by this mechanism.
For example, neural tube defects result from the failure of the neural folds to meet in the midline of the spine (at approximately 22 days' gestation), cleft palate results from the failure of the lateral palatine processes (shelves) to reach the midline of the palate (between the 9th and 12th weeks of gestation), cleft lip is caused by a failure of the maxillary prominences to meet and fuse (during the 6th and 7th weeks of gestation), and obstructive defects of the urinary tract result from failure of the ureters to grow to sufficient size and to cannulate (between 4 and 8 weeks' gestation). 31 Limb reduction defects have a variety of causes but often result from incomplete morphogenesis (reduced growth) or disrupted morphogenesis. Disrupted morphogenesis can result from reduced blood supply to or vascular occlusion of the developing limb 32 ; thrombophilia and vascular occlusion are also associated with folate or the C677T MTHFR mutation. The type of cardiac defect previously associated with this folate nutriture (perimembranous ventricular septal defects) is also consistent with this theory, because ventricular septal defects result from growth failure: Extensions of subendocardial tissue fail to grow from the right side of the fused endocardial cushion and do not fuse with the muscular part of the interventricular septum. 31 If this theory is correct, it is possible that other congenital defects resulting from impaired or delayed growth (delayed timing of developmental events) or hypomethylation-related altered gene expression could also be caused by the C677T MTHFR mutation. Potential defects include schisis defects, such as omphalocele, gas- 28 who analyzed data from two populationbased case-control studies of periconceptional multivitamin supplementation to determine whether supplementation could reduce the incidence of nonsyndromic neural tube defects occurring in association with other malformations (which they called neural tube defect multiples). They found that vitamin supplementation did reduce the incidence of neural tube defect multiples and that the associated defects apparently prevented by supplementation were cleft lip and palate, omphalocele, gastroschisis, diaphragmatic hernia, esophageal atresia, anorectal atresia, renal agenesis, urinary tract defects, genital defects, and cardiac anomalies.
The multiple functions of the methyl groups derived from this single pathway indicate far-reaching consequences of the C677T MTHFR mutation. For example, if it is determined that a woman who has a child with any of the previously discussed congenital defects carries the C677T MTHFR mutation, in addition to an increased risk of having other affected children she may also be at risk for such personal health problems as cardiovascular disease or major depression. The reverse is also possible, in that women with cardiovascular disease or depression may be at increased risk of carrying a child with one of these related birth defects.
This pathway also illustrates beautifully the interaction of genes and environment. Our interest in the link between cardiac defects and the C677T MTHFR mutation began after we completed a study examining the possible relationship between maternal cardiovascular disease and fetal neural tube defects, mediated by the MTHFR gene. 33 We unexpectedly discovered that chronic hypertension was not more likely to develop in mothers of children with neural tube defects but was more likely to develop in mothers of children with congenital heart defects. We then realized that women who have borne a child with a neural tube defect are instructed to ingest folic acid, which possibly has the additional benefit of preventing cardiovascular disease in these susceptible women, whereas this recommendation is not made to women who have borne a child with a heart defect. In the case of neural tube defects it has been demonstrated that it is possible to reduce the risk imposed by genetic background by improving environmental factors (folic acid supplementation 4, 5 ) ; it now appears possible that the risk of a variety of congenital abnormalities and several adultonset diseases may be reduced in a similar manner. Because the majority of genetic traits are now believed to be multigenic or multifactorial, this situation may serve as a paradigm of how knowledge of the influences on gene function can be used to clinical advantage and how manipulation of the environment can mitigate increased risk imposed by heredity.
In conclusion, the same mechanism responsible for the major portion of isolated neural tube defects, involving the C677T MTHFR mutation and high homocysteine levels, appears to be responsible for a portion of cardiac defects as well. Further research is needed to confirm these findings and to investigate the possible link between this mutation and other multifactorial congenital structural abnormalities. Discussion DR LAWRENCE D. PLATT, Los Angeles, California. Known causes of birth defects include gene mutations, chromosomal abnormalities, teratogenic agents, and maternal factors; however, the etiologies of approximately 70% of congenital defects remain unexplained. As demonstrated in Wenstrom et al's article, however, recent findings hold promise to elucidate some of the unknown causes relating to birth defects. The article represents an exciting and emerging area of research in the etiology of congenital anomalies, the relationship of homocysteine and the C677T MTHFR gene to multifactorial congenital heart defects. This subject is of particular significance with the realization that birth defects are the leading cause of infant mortality, with cardiovascular defects accounting for 1 in every 3 birth defect-related infant deaths. 1 In terms of economic expenses, the average cost per new case of the most clinically important cardiovascular defects (in 1992 dollars) is $344,500. 2 Of further import is the fact that even though overall infant mortality has declined during the past 20 years, mortality attributable to birth defects has not declined as rapidly. During the period extending from 1979 through 1998, overall infant mortality declined 44.9%, whereas infant mortality attributable to birth defects declined only 38.3%. 1 Studies suggesting that environmental and genetic factors have a joint role in the causation of congenital anomalies were initiated >30 years ago. 3 With epidemiologic evidence demonstrating that neural tube defects were observed in an increased incidence in lower socioeconomic groups, a relation was made between poor nutrition and the risk for neural tube defects, with the first studies implicating the use of folic acid supplementation to prevent the occurrence of neural tube defects being initiated in the early 1980s. [4] [5] [6] The British Medical Research Council-sponsored trial 7 in 1991 indicated that women who ingested 4000 µg folic acid daily had a 72% protective effect of neural tube defects. Further, Czeizel and Dudas 8 reported that women who took a multivitamin containing 800 µg folic acid had a significantly lower risk of a first occurrence of a neural tube defect than did women who did not. After these reports, studies were generated to identify the genetic and biochemical bases of neural tube defects. With studies by Steegers-Theunissen et al 9 and Mills et al 10 showing that women who had a history of offspring with neural tube defect had increased blood levels of homocysteine, research efforts focused on the metabolic cycle in which homocysteine undergoes remethylation to methionine, with significant investigative efforts being placed on MTHFR. Homozygosity for the C677T MTHFR allele was then reported to be associated with an increased risk of neural tube defects. 11 Recent efforts have been made to show an association between supplemental vitamin usage and reduced occurrence of some heart defects, oral clefts, urogenital anomalies, and limb deficiencies.
In this study Wenstrom et al hypothesized that the C677T MTHFR mutation and increased levels of homocysteine are causally linked to isolated congenital cardiac malformations. To ascertain the validity of this supposition, they performed a retrospective study comparing amniotic fluid homocysteine levels and MTHFR genotypes between a control group consisting of women with normal fetuses and a study group composed of women with fetuses diagnosed with isolated cardiac malformations at the University of Alabama Prenatal Genetics Clinic from January 1988 through January 1998. The control group in this study had served as control subjects in several previous investigations, and their amniotic fluid homocysteine levels and MTHFR genotypes were therefore on record. A comparison of maternal race and the length of storage of the amniotic fluid samples revealed no significant differences between the study and control groups. The mean homocysteine level and the incidence of abnormal MTHFR genotype, (as either heterozygous or homozygous) were determined for the study group and compared with the control values. The study revealed that relative to the control group the study group had a significantly greater number of cases with an amniotic fluid homocysteine level >90th percentile, an abnormal MTHFR genotype, either an increased homocysteine level or an abnormal genotype, or both an increased homocysteine level and an abnormal MTHFR genotype. Wenstrom et al concluded that the same mechanism related to neural tube defects involving the C677T MTHFR mutation and elevated amniotic fluid homocysteine levels is also associated with certain cardiac defects.
To their credit, in a confluence of embryonic development, molecular genetics, and biochemistry, the data of Wenstrom et al provide evidence of the relationship of the MTHFR genotype, homocysteine levels, and congenital heart defects. I do, however, have the following questions for Dr Wenstrom:
1. With regard to the comparability of study groups, the study relies on a convenience sample rather than a population-based sample. The study is composed of in- Table I . International birth prevalence rates of neural tube and heart defects from 1980 through 1996 21 1980-1984 1985-1989 1990-1994 1995 1996 England fants chosen by availability and the use of prenatal diagnosis, as opposed to a random sample of the population. Isn't this approach likely to introduce bias and decrease the generalizability of the findings? Second, the control group consisted of subjects who served as control subjects in previous studies associating the C677T MTHFR mutation with neural tube defects. These subjects had normal pregnancies and were matched with the preceding set of case patients with pregnancies complicated by neural tube defects for race, date of amniocentesis (year and month), and maternal age. The study indicated that the 2 study groups were matched for maternal race and length of storage of the amniotic fluid samples. Other investigators 12, 13 have demonstrated that variations in C677T MTHFR allele frequency are also dependent on geographic region and racial or ethnic group (eg, the frequency of C677T MTHFR homozygotes is ≥20% among Italians and some Hispanic groups but is only 1% to 2% among African Americans). Further, there exist a number of confounding variables that could have a significant association with the measured homocysteine levels or congenital heart defect rates. These include the year of amniocentesis, maternal age, maternal education, vitamin use and timing of use, socioeconomic status (median income level), and maternal chronic illness. Can the comparability of the subjects in the study and control groups be justified without controlling for these additional variables? Finally, in terms of sample selection the frequency of congenital heart defects associated with other structural anomalies among live births has been reported as 20%. 14 In a recent analysis of the range and frequency of congenital heart defects in aborted and stillborn fetuses, however, 66% of 129 case patients examined had associated extracardiac anomalies, 66% had additional cardiac malformations, and 33% had chromosomal abnormalities, whereas only 9% had isolated cardiac defects. 15 In light of the high incidence of congenital heart defects in association with other defects, why was the inclusion of subjects limited to only those fetuses with isolated cardiac defects? 2. Mean plasma homocysteine concentrations have been found to be significantly higher than those in corresponding amniotic fluid samples, with a positive correlation established between the homocysteine concentrations in the two compartments. [16] [17] [18] Wouldn't maternal plasma have been a more suitable medium for the quantification of homocysteine levels than amniotic fluid? In terms of sample analysis, Fiskerstrand et al 19 have presented data on the kinetics of production and release of homocysteine from blood cells into plasma or serum at room temperature. Their findings demonstrated significant increases in total plasma homocysteine concentration when whole blood was stored at room temperature for 4 hours. Description of the procedure used in the homocysteine assays in this investigation indicate that amniotic fluid samples were prepared for assay or storage within 6 hours of performance of the amniocenteses. In view of the effects of time and temperature on the stability of total plasma homocysteine in whole blood, are any data available that could indicate the stability of total plasma homocysteine in amniotic fluid for a maximum of 6 hours before either assay or storage at -20°? Second, the samples were stored for an average of 4.9 years and as long as 11 years in some cases. Is homocysteine known to be stable in amniotic fluid during prolonged storage?
3. Although this is unconfirmed, it has been suggested that the risk for spina bifida may depend on the genotypes of both the mother and her child. The data of Christensen et al 20 indicate that the risk of spina bifida is increased 6-fold when both the mother and infant are homozygous for C677T MTHFR allele. In contrast, the odds ratio for neural tube defects was 1.3 when only the mother was homozygous for the allele. Is there any evidence that such an interaction may exist in predicting the risk for congenital heart defects?
4. The birth prevalence rates in selected countries of neural tube defects and selected congenital heart defects (transposition of the great arteries and hypoplastic left heart syndrome) from 1980 through 1996 are listed in Table I . 21 The countries included in this table were chosen on the basis of having instituted a national policy on folic acid supplementation or enrichment of foods. Although folic acid supplementation policies may not have been in effect for an adequate period in all countries to observe temporal changes in the prevalence of these defects, it is interesting to note that the prevalence of neural tube defects has for the most part decreased through the years. A concomitant decrease cannot be observed for all countries, however, in terms of the prevalence of congenital heart defects. If folic acid ingestion plays a role in the reduction of risk for congenital heart defects, wouldn't a change in the prevalence rate of cardiac defects more closely mirror the relatively consistent decrease in the prevalence of neural tube defects?
In summary, I congratulate Wenstrom et al on an important contribution to our understanding of the etiology of birth defects. This, along with other outstanding work in the area of prenatal diagnosis, will surely lead us to important results-the reduction of birth defects and their contribution to perinatal mortality. DR RICHARD BULLER, Iowa City, Iowa. I have two questions. First, you spoke of the C677T MTHFR mutation. What are the in vitro biochemical data that indicate that this a mutation, as opposed to a polymorphism? Second, you counted both homozygous and heterozygous individuals as having an abnormal gene. Twenty percent of your control population also had an abnormal gene. Were any of those subjects homozygous? If so, would you care to speculate as to why they had no defects? DR MARTIN STONE, Watermill, New York. I have a historical comment to add to this topic. More than 30 years ago I presented an article to get into this Society, entitled "Folic Acid Metabolism and Pregnancy." We were able to show in our study that there were adverse pregnancy outcomes, both maternal and fetal, among patients who had low folate levels. This followed the work of Hibbard and Smithells, who showed on the maternal side increases in abruptio placentae and spontaneous abortions. It is nice to hear a great scientific study well presented that confirms what was observed clinically, although the emphasis here of course was on the defects. DR JAMES MARTIN, Jackson, Mississippi. My questions are simple. First, does the presence of the mutation or elevated homocysteine level have any implication for prognosis for these children as they have repairs done for these defects? In other words, does the slowed growth affect their surgical repairs and health later? Second, when you did not find the presence of this mutation or an elevated homocysteine level, was there any relationship between any other disease (eg, diabetes) and heart defects?
DR JAMES ROBERTS, Pittsburgh, Pennsylvania. I have two questions. First, I thought the concept that reduced methionine might be involved was interesting. Are there data to suggest that blood levels of methionine are lower in individuals either homozygous or heterozygous for the mutation? Second, is there any relationship between the zygosity of the individual and amniotic fluid homocysteine levels? Aren't the blood levels of homocysteine normal in the heterozygotes?
DR RICHARD BERKOWITZ, New York, New York. As a variant of Dr Platt's last question, if both neural tube defects and isolated congenital heart diseases are caused by a defect in the same gene, why don't we see the two clinical entities linked more often? Why is it so uncommon to see both cardiac disease and neural tube defects in the same fetus?
DR SHERMAN ELIAS, Chicago, Illinois. In your matched control study, did you try to control for folic acid or multivitamin intake?
DR STEVE CARITIS, Pittsburgh, Pennsylvania. First, is it maternal or fetal hyperhomocysteinemia that creates the problem? I don't think you can tell. Second, if we rely on maternal homocysteine levels in terms of both diagnosis and treatment, should we measure homocysteine levels? Or should we just treat everybody who is heterozygous or homozygous for the C677T MTHFR mutation with folic acid regardless of homocysteine levels? DR WENSTROM (Closing). I'll discuss Dr Platt's questions first. He noted that we used a convenience sample instead of a population-based sample and wondered whether this could bias results. It is true that we had to use a convenience sample, but that is because congenital heart defects are relatively infrequent, especially the kind we studied-multifactorial and not associated with any known syndrome or other defects. It took us 10 years to collect the cases we had. However, a convenience sample would have been bad only if what we were trying to do was determine the population incidence of this mutation, which we were not. We were simply trying to test for an association between this mutation and cardiac defects. A convenience sample for this kind of an analysis is acceptable, as long as the control subjects are chosen properly.
That leads to his second question, about the fact that we used these control subjects in a previous study. Could they have possibly been different in some way that could have influenced the results? It is true that we used these subjects previously, but we looked at them again to see whether they were similar to the case patients in all im-portant ways before we looked at the results from the previous analysis. We found that they were similar in all ways that could have influenced the results. The control subjects were seen in the same clinics as the case patients. Both case patients and control subjects were considered to be at high risk for fetal birth defects. All were from the same geographic region; all came from Alabama, and most come from our own county. They had the same insurance payors and socioeconomic status mix, which probably influences diet. They were seen during the same period. Most important, they were matched for maternal race, which is probably the most important factor influencing the presence or absence of this mutation. The mutation is found less frequently among African Americans than among whites, and there were similar numbers of those racial groups in both case and control groups.
Most important, all these data were collected prospectively. We have a computerized genetics database that is linked to an obstetric outcomes database. So the data were collected as they occurred, in a prospective manner. Even though we analyzed the data retrospectively, there was no concern about possible recall bias.
Dr Platt next asked why we did not include congenital heart defects that occurred in association with other defects. As he pointed out, there are already many known genetic causes of cardiac birth defects, such as aneuploidy, chromosome duplication or deletion syndromes, teratogenic exposure, and, as Dr Martin pointed out, maternal illnesses such as diabetes. Our goal with this preliminary study was to see whether this mutation by itself, without the influence of all those other factors, could cause a birth defect. That is why we carefully chose cases in which there was absolutely no other explanation for the heart defect. I think that answers Dr Martin's question as well. None of these women had diabetes or were taking any medications that could have been teratogenic. Dr Platt's fourth question was why did we not study maternal serum homocysteine levels, because there is some correlation between maternal homocysteine levels and amniotic fluid levels? We wanted to study the fetus first, because our theory was that it is the fetal microenvironment during tissue differentiation that is most important in causing a birth defect. The cells that we sampled and tested genetically were fetal cells, and we think that most of the homocysteine in the amniotic fluid was fetal in origin.
Another of Dr Platt's questions was whether there is any evidence that the maternal-fetal interaction can cause heart defects. This is linked to the previous question, because homocysteine can cross from the maternal circulation into the amniotic fluid and possibly to the fetus. There have been cases of mothers with homocysteinuria who had fetuses exposed to high amniotic fluid levels of homocysteine, even though the fetuses did not inherit that disease. The question thus is, if the mother has the mutation and the fetus does not, could that possibly cause the birth defect? I suppose that it is possible. There were 4 cases in this current series with a high amniotic fluid homocysteine level, even though the fetus did not have the mutation. In a previous study of neural tube defects we also had several cases with high amniotic fluid homocysteine levels even though the fetus did not carry the MTHFR mutation. If homocysteine can have a toxic effect, then perhaps the maternal homocysteine status did affect fetal development in these cases. Another explanation, however, is that those amniotic fluid homocysteine levels were high because the fetuses had a different mutation in the MTHFR gene. van der Put et al have now reported a second mutation in this gene that has similar effects. Obviously, the best way to answer this question is to study mothers and fetuses simultaneously, and we will do that in the future.
The next couple of questions were about how we handled our fluids. Dr Platt cited an article by Fiskerstrand et al showing that homocysteine levels rise when blood samples are left on the bench for 4 hours. I believe that the authors said that the elevation in homocysteine levels was caused by red blood cell lysis, which occurs when blood is left at room temperature. We had no or negligible red blood cells in our amniotic fluid samples. In addition, we did not leave them at room temperature. We kept them in the refrigerator until they were frozen.
The second question was about sample storage. These samples were frozen for many years, a mean of almost 5 years, and some longer than that. Is homocysteine stable in prolonged storage? Yes, it is. Frosst et al in their 1995 article showed that homocysteine in fluids stored in this way is stable indefinitely, as long as the sample is not thawed and frozen repeatedly. We store all our samples in aliquots, so that each sample is thawed only once for analysis.
Dr Platt showed a table from the International Clearinghouse for Birth Defects annual report that shows the incidence of neural tube defects and heart defects in many different countries at several periods starting with 1980 to 1984. The incidences of neural tube defects have decreased, whereas the incidences of heart defects have stayed the same. These figures seem to imply that we are preventing the development of fetuses with neural tube defects though our folic acid supplementation strategies. When you look closely, however, you can see that the neural tube defect incidence started to decrease in 1984, although most countries were not advocating folic acid supplementation until 1994. Dr Smithells, who heads the neural tube defect committee of this group, opined that even if everybody was using folic acid as instructed, the first year that we would have expected to see any decline in neural tube defect incidence would have been 1996. However, we can see that the incidence of neural tube defects started declining in the 1980s.
I think that we can determine why these defects declined if we look at the way these data were collected. Each different country has its own system of collecting birth defects information. Each country has its own gestational age cutoff before which they do not collect data, and that causes a discrepancy. France does not collect data from any pregnancies ending at <22 weeks' gestation. England and Wales do not collect any data at <24 weeks' gestation. Hungary and Israel do not collect information on any pregnancies that end at <28 weeks' gestation. So pregnancy terminations are not included in these data. The
